Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.28)
# 365
Out of 4,869 analysts
231
Total ratings
41.04%
Success rate
20.95%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $4.79 | +234.03% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $7.00 | +42.96% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $8.26 | +263.20% | 6 | May 14, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $9.04 | +176.55% | 2 | May 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $50.20 | +123.11% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $18.93 | +21.50% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $20.08 | +303.39% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.46 | +184.55% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $79.98 | +53.79% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $2.67 | +3,270.79% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.85 | +145.61% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $51.60 | +155.81% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $17.74 | +40.92% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $37.14 | +217.72% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $32.28 | +11.52% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $20.50 | +226.91% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.64 | +272.34% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $10.08 | +187.70% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.25 | +423.08% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.07 | +647.66% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $14.21 | +308.16% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.29 | +381.40% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.89 | +205.60% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $2.16 | +548.15% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.31 | +462.77% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.50 | +1,300.00% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.95 | +531.58% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.71 | +1,073.02% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.92 | +687.67% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.05 | +85,614.29% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.69 | +5,824.86% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.37 | +11,769.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.77 | +10,924.64% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.13 | +2,424.54% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.20 | +3,650.00% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.06 | +937.74% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.45 | +4,037.93% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.46 | +6,064.38% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.87 | +134,659.36% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.51 | +31,358.91% | 1 | Jan 9, 2020 |
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $4.79
Upside: +234.03%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.00
Upside: +42.96%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.26
Upside: +263.20%
Zevra Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $25
Current: $9.04
Upside: +176.55%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $50.20
Upside: +123.11%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $18.93
Upside: +21.50%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $20.08
Upside: +303.39%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.46
Upside: +184.55%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $79.98
Upside: +53.79%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $2.67
Upside: +3,270.79%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.85
Upside: +145.61%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $51.60
Upside: +155.81%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $17.74
Upside: +40.92%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $37.14
Upside: +217.72%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $32.28
Upside: +11.52%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $20.50
Upside: +226.91%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $5.64
Upside: +272.34%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $10.08
Upside: +187.70%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.25
Upside: +423.08%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.07
Upside: +647.66%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $14.21
Upside: +308.16%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.29
Upside: +381.40%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.89
Upside: +205.60%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $2.16
Upside: +548.15%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $2.31
Upside: +462.77%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.50
Upside: +1,300.00%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.95
Upside: +531.58%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.71
Upside: +1,073.02%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.92
Upside: +687.67%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.05
Upside: +85,614.29%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.69
Upside: +5,824.86%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.37
Upside: +11,769.44%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.77
Upside: +10,924.64%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.13
Upside: +2,424.54%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.20
Upside: +3,650.00%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.06
Upside: +937.74%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.45
Upside: +4,037.93%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.46
Upside: +6,064.38%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.87
Upside: +134,659.36%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.51
Upside: +31,358.91%